顕微鏡

MiCAN Technologies

providing high precision artificial blood cells using hIPSc technologies

Details

OVERVIEW

A world leading company based in Kyoto and Kobe, the heart of the sciences and technologies for regenerative medicine, now provide iPS derived high functional cell products to the global market. 

Optimised artificial blood cells from iPSC

NEW - COVID-19 optimised product (cMylc)​

Welcome to collaborative research projects

Made in Kyoto and available to the global market

KEY TECHNOLOGIES

MiCAN developed and optimised our unique methodologies to obtain reproduceable iPSC derived myeloid (immature dendritic cells) with cryopreserved format convenient for the scientists internationally.

Optimised artificial immature blood cells from iPSC

  1. Unique and patented differentiation methods​

  2. Special immortalizing technology

  3. Cryopreservation for the global supply

  4. Supplied as ready-to-use format

Mylc

MiCAN's core technology to prepare reproduceable immature dendritic cells derived from stem cells including human iPSC. Mylc provides high-sensitivity for TLR ligands.

Key applications

Infectious disease

DENV (dengue) research

(infection, ADE detection, cell reaction)

Immune, allergy, inflammation fields

Safety test for

endotoxin (LPS assay)

skin hypersensitivity

Immune activity assay

cMylc

Exclusively optimised Mylc cells suitable for COVID-19 (SARS-CoV-2 virus) research for vaccine and drug discovery.

Key applications

Infectious disease

SARS-CoV-2 research

(infection, ADE detection, cell reaction)

Immune, allergy, inflammation fields

Cytokine analysis introduced by COVID-19 virus infection

APPLICATIONS

ADE detection for SARS-CoV-2

For CoV-2 vaccine research with detecting antibody-dependent enhancement (ADE).

ADE is a phenomenon when binding a virus to suboptimal antibodies enhances its entry intro host cells, followed by its replication. (Also called immune enhancement or disease enhancement.) Reproducing ADE reactions in vitro was difficult in safety tests in many infectious disease area. Our data shows that cMylc could detect this ADE reaction.

Skin sensitization test

Higher correlation with LLNA animal test.

Significantly higher correlations were observed between Mylc and animal test (LLNA potency) than using existing cell based assay (h-CLAT: CD86/CD54) with reducing risks to detect fault-negative and fault-positive results.

Infection with SARS-CoV-2

Viral RNA detection from supernatant of the infected cell culture. Significant increase of progeny viruses were observed on cMylc-DC with further differentiation.

Endotoxin detection (LPS)

Lipopolysaccharide, high sensitive cell-based colorimetric assay

We are proud to share this data that our Mylc cells is confirmed to show higher sensitivity in MAT assay (major LPS detection method without using animals) with detecting IL-6 production at very low concentration rather than Mono-Mac-6 and THP-1, which are used widely in pharmaceutical research.

Immuno-stimulation assay

Higher detection with lower concentration of the objective ingredients.

With a collaboration to a major food industry that Mylc detected immuno-stimulation with their active ingredients.

DENV infection assay

ADE (antibody-dependent enhancement) detection

MiCAN recently published a unique data set with our academic collaborators in Osaka, Kumamoto and Thailand that the Mylc cells derived from hIPSC showed higher sensitivity to detect dengue virus (DENV) compared to Vero and K562 cells.

LOGISTICS

Now available for the global market with optimising cryopreservation formatting and managing the global supply chain.